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Fewer than 5% of cancer patients participate in clinical trials, making it challenging to test new therapies
or interventions for cancer. Even within that small number, patients living in inner-city and rural areas
are underrepresented in clinical trials. This study explores cancer patients' awareness and perceptions of
cancer clinical trials, as well as their perceptions of patient-provider interactions related to discussing
cancer clinical trials in order to improve accrual in cancer clinical trials. Interviews with 66 former and
current in inner-city and rural cancer patients revealed a lack of awareness and understanding about
clinical trials, as well as misconceptions about what clinical trials entail. Findings also revealed that
commercials and television shows play a prominent role in forming inner-city and rural patients' atti-
tudes and/or misconceptions about clinical trials. However, rural patients were more likely to hold
unfavorable views about clinical trials than inner-city patients. Patient-provider discussions emerged as
being crucial for increasing awareness of clinical trials among patients and recruiting them to trials.
Findings from this study will inform communication strategies to enhance recruitment to cancer clinical
trials by increasing awareness and countering misconceptions about clinical trials.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The need for high-quality scientific evidence to support clinical
and policy decisions has steadily increased over the last century,
and is currently highly demanded by patients, providers, insurers,
the pharmaceutical and medical equipment industry, and policy
makers [46]. Clinical trials are still the golden standard by which
the efficacy of any clinical intervention is assessed [30]. According
to the [6]; cancer is the second leading cause of death in the United
States, and significant material and human resources are dedicated
to finding a cure or to improve the quality of life of patients.
Nevertheless, when it comes to search for novel cancer therapies,
participation in cancer clinical trials is very limited, with less than
five percent of U.S. adult cancer patients enrolled in clinical trials
[4]. Evenwithin that small number, patients living in inner-city and
rural areas are underrepresented in clinical trials, most likely due toInc. This is an open access article uthe limited availability of trials at the medical centers serving their
communities and to patients' minimal interest in participating in
these studies [36]. In contrast, suburban areas have been found to
have the highest level of clinical trial participation [40]. The current
state of cancer clinical trial participation reveals a critical need to
increase recruitment in inner-city and rural areas.
Patients' awareness and perceptions of clinical trials, as well as
attitudes of physicians, are some of the most important factors
underlying low recruitment rates of patients into clinical trials [1,3].
There is a dearth of studies exploring awareness and perceptions of
cancer clinical trials among patients in general, and among inner-
city and rural patients in particular (see Refs. [23,27,31,50]. In
addition, most of the limited number of studies conducted on these
populations have either used quantitativemethods such as surveys,
thus limiting the depth and nuances of findings, or included mostly
members of the non-diseased general population, thus limiting the
voice of cancer patients.
Focusing on clinical trial investigators' perceptions of perceived
barriers to clinical trial recruitment among rural and African-nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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studies should qualitatively examine how African Americans, as
well as rural residents, perceive the concept of medical research, in
an effort to determine how best to move forward with appropriate
CT [clinical trial] recruitment strategies” [44]; p. 93). Previous
qualitative research exploring underserved populations' percep-
tions of clinical trials were mostly exploratory due to the small
sample size of cancer patients participating in them, usually about
20 participants total (e.g., [25,32,37].
This study aimed to address these limitations by (1) focusing on
inner-city and rural cancer clinics, (2) interviewing only current and
former cancer patients, and (3) recruiting a larger number of par-
ticipants than in previous qualitative studies. More specifically, this
study explored patients' awareness and perceptions of cancer
clinical trials, as well as their perceptions of patient-provider in-
teractions related to discussing cancer clinical trials. Findings from
this study provide insight to the development of tailored regional
communication strategies to improve accrual to cancer clinical
trials among inner-city and rural patients. Indeed, as [25] recently
stated, “the goal of future research should be to develop, apply, and
refine theoretical and audience-based approaches to message
design that will reduce the cancer health inequities of themedically
underserved” (p. 1174). The present study represents a first step in
that direction.
1.1. Barriers to participating in cancer clinical trials
Lack of trust and awareness are often cited as main reasons
underserved populations do not participate in clinical trials [13].
Furthermore, physicians actively informing patients about and
discussing the availability of clinical trials, as well as provider-
patients interaction, have been identified as the most important
factors promoting accrual [20,22]. While some patients may have a
general cognizance of clinical trials, they may not be aware of
clinical trials that are relevant to them. One national study of cancer
patients reported that an astounding 85% of respondents were
unaware that participating in a clinical trial was an option for them
[42]. Other studies suggested that if patients were offered an op-
portunity to enroll in a trial, they would be inclined to participate
[8] but that the complexity of research protocols and cost associ-
ated with participating in a clinical trial represented important
barriers to overcome [49]. Recently publicized data from the Me-
morial Sloan Kettering Cancer Center states that only one in four
Americans have a positive impression about clinical trials
(N¼ 1501) and that over half of their surveyed physicians (N¼ 600)
considered clinical trials only late in treatment [5].
For most research, increasing clinical trial study awareness for
both oncologists and patients is one of the most recommended
measures to improve the activation process and to promote accrual
[10]. At community-based cancer centers, increased efforts need to
be focused on educating and encouraging physicians, educating
patients, as well as to increase the availability of clinical trials [17].
At a patient level, having the adequate information, presented in
timely manner in an easy-to-understand, friendly format, may help
decision making by increasing awareness and addressing some of
the barriers related to low health literacy [11].
Several patient-provider centered factors have been also iden-
tified as affecting clinical trial accrual. While oncologists' referral
for clinical trials is essential for effective recruitment, many doctors
may be reluctant to refer because they perceive clinical trials as an
excessive administrative or financial burden to their practice [24] or
because of assumptions about patient eligibility to enroll or con-
cerns that a challenging social support system will adversely affect
the patient's ability to adhere to the study protocol [21].
Health communication has made impressive progress in the last15 years and research on communication interventions have
received significant support from the NIH, although studying
accrual to cancer clinical trials has been ominously overlooked [38].
Nowadays, patients have a multitude of sources available from
which to get information about health topics [16,39]. Nevertheless,
cancer patients' needs and interests present much variability, with
only a minority of patients interested to learn as much as possible
about their disease, and most of them depending on their physician
for information [28].
As mentioned earlier, the purpose of this study was to examine
inner-city and rural patients' awareness and perceptions of clinical
trials to support the development of a regional communication
strategy to improve accrual to cancer clinical trials. To this end, this
study aimed to investigate the following two main research
questions:
RQ1. Where do current and former inner-city and rural cancer
patients obtain information about clinical trials and what they
know about them?
RQ2. How do current and former inner-city and rural cancer pa-
tients perceive clinical trials?2. Method
Data were collected by conducting phone and face-to-face,
semi-structured interviews with current and former cancer pa-
tients between June and August 2015. The research team recruited
participants from an inner-city and a rural oncology clinic in the
Midwest using a combination of network and convenience sam-
pling techniques with the help of research nurses, whowere part of
the research team and who contacted potential participants by
mail, phone and/or in person. Any current or former cancer patients
from those two clinics were eligible to take part in the study,
regardless of type of cancer or treatment, as well as prior partici-
pation in a cancer or non-cancer clinical trial. Current patients were
recruited on site by the research nurses who told potential partic-
ipants about the study. Former patients first received a letter in the
mail about the study andwere then contacted by phone by research
nurses to see if they would be willing to participate in the study.
Two research teammembers contacted the patients who agreed to
participate to schedule a day/time for the interview. Participants
provided consent twice: during the first step of the recruitment
process and again before the interviews. The Institutional Review
Board approved all recruitment documents (i.e., recruitment letter;
phone call script) and materials (i.e., information statement;
interview questions) related to the study.
A total of 100 current and former cancer patients agreed to
participate and interviews were conducted with 66 of them (32
from the inner-city clinic and 34 from the rural one), as attempts to
schedule or to conduct interviews with others were not successful,
even after multiple attempts. Recruitment stopped when data
collected from both groups of participants did not yield any new
information, thus demonstrating data saturation, which refers to
the idea that enough information has been collected to replicate the
study [15]. While qualitative researchers recommend interviewing
20 to 30 participants as a broad rule of thumb [9], there is no for-
mula or set number of participants to reach data saturation, as it
depends on a study's research questions. Therefore, data collection
and participant recruitment continues until “depth as well as
breadth of information is achieved” [35]; p. 3). All participationwas
voluntary and no compensation was provided as an incentive. The
majority of the interviews (n ¼ 55; 83.33%) took place by phone.
Face-to-face interviews were conducted in private chemotherapy
stations at the inner-city clinic. Two research team members
Table 1
Participants' characteristics by place of residence.
Inner-city participants Rural participants
Gender
Male (n) 12 13
Female (n) 20 21
Race/Ethnicity
White-American (n) 14 33
African-American (n) 16 1
Hispanic-American (n) 2 0
Age
Mean (standard deviation) 54.77 (10.66) 67.15 (12.07)
Range 28e69 37e89
Education
Median High school diploma Some college
Annual Income
Median $10,001 - $20,000 $20,001 - $40,000
Previously participated in clinical trial
Yes 4 2
No 28 32
1 This may be because of the six participants who reported having been part of a
clinical trial, only one was for a cancer clinical trial.
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and a trained doctoral candidate with experience interviewing
members of marginalized groups in the context of health
communication conducted the other interviews (n ¼ 17; 25.76%)
when there was a conflict of schedule between the participants and
the two research team members. The average interview time was
about 18 min.
Participants answered a series of open-ended questions per-
taining to their knowledge and perceptions of clinical trials in
general and cancer clinical trials in particular. Participants also
answered questions about their sources of and access to health
information. The research team adapted questions from previous
health communication studies exploring overall awareness of, at-
titudes towards, and (potential) participation in cancer clinical
trials (e.g., [33,34,41,43,47]. At the end of the interview, participants
answered demographic questions. All interviews were audio-
recorded and transcribed using pseudonyms to protect partici-
pants' confidentiality. The data of the study amounted to 481
double-spaced pages of transcript.
The two research teammembers who conducted the interviews
analyzed the data in ATLAS.ti (version 6.2), software that assists in
organizing and making sense of qualitative datasets. Researchers
first coded participants' answers in chronological order during the
data collection period using a combination of “open coding,”
identifying relevant themes line by line, and “focused coding,”
searching for specific themes to group them into categories [7,14].
After completing all 66 interviews, the researchers also coded the
data using “theoretical coding,” more analytical codes to gain more
insight about participants' knowledge, attitudes and beliefs of
clinical trials [14]. Open and focused coding allow researchers to
analyze the data while continuing the data collection in order to
further explore the emerging themes/codes in subsequent in-
terviews, while theoretical coding help make sense of participants'
responses by exploring larger connections among codes and
generating more conceptual codes linked to health communication
theories. Researchers met throughout the data collection and
analysis phase to compare notes and ensure that similar themes
were coded in similar ways. They also shared codes with the
research team to obtain feedback on interpreting participants' re-
sponses. The research team then compared the final codes that
emerged from the data analysis based on their frequency for inner-
city and rural participants.
2.1. Participants' demographics
Inner-city (n ¼ 32) and rural (n ¼ 34) study participants were
equally divided in terms of gender, with 20 and 21 women, and 12
and 13 men, respectively. Table 1 presents participants' de-
mographic characteristics based on place of residence. Inner-city
participants included 16 African Americans, 14 White Americans
and 2 Latino Americans. Their age ranged from 28 to 69 (M¼ 54.77;
SD¼ 10.66). Rural participants were older; their age ranged from 37
to 89 (M¼ 67.15; SD¼ 12.07), and all wereWhite Americans except
for one African American. Most rural participants had received at
least some college education (n ¼ 24) and overall reported a me-
dian annual income between $20,001 and $40,000. Most inner-city
participant had not gone to college (n ¼ 23) and overall reported a
median annual income between $10,001 and $20,000. The majority
of participants (n ¼ 60) had never taken part in a clinical trial (see
Table 1).
3. Findings
The study's research questions dealt with where participants
obtain clinical trial information and what they know about them(RQ1), and how they perceive clinical trials (RQ2). Table 2 presents
themain categories and codes based on frequency and participants'
place of residence. Differences among codes based on participants'
demographic variables such as educational and income levels were
also taken into account by isolating responses from inner-city
participants and rural participants. No in-group differences were
found among the codes based on those variables. In addition, par-
ticipants' responses were also compared according to prior
participation in clinical trials. Interestingly, participants who had
been part of a clinical trial did not seem to have a better or worse
understanding of clinical trials than participants who had never
taken part in a clinical trial.1
The codes represent the main themes from the findings and are
organized in two overall categories: awareness and perceptions of
clinical trials. Findings are presented below based on category, code
and participants' place of residence. Within each category, the
codes/themes that emerged as common to both inner-city and rural
participants are discussed first, followed by the codes/themes that
were different between inner-city and rural participants. Findings
are thus discussed in the order in which they are presented in
Table 2. Each first mention of a participant's name in a new para-
graph is followed with his/her place of residence in parentheses.
3.1. Awareness of clinical trials: similarities between inner-city and
rural participants
Overall, inner-city and rural participants reported similar levels
of awareness about clinical trials, mainly learning about them via
the media and personal experiences. Inner-city and rural partici-
pants also reported overwhelmingly relying on doctors and nurses
for information about their health. Lastly, about half of inner-city
and rural participants mentioned searching for health informa-
tion online.
3.1.1. Learning about clinical trials in the media
The most common source of information about clinical trials in
general for both inner-city and rural participant was mediated
advertisements for industry-sponsored trials. For instance, Patricia
(inner-city) said that she sees “ads on TV on recruitment to clinical
trials for other things [not cancer clinical trials] all the time.”
Similarly, Christopher (rural) stated, “every now and then I see in
Table 2
Topic relevance of the two patient samples based on frequency and residence.




Category: Source of information/Awareness
Similarities between inner-city and rural participants
Learning about clinical
trials in the media
19 15
Learning about clinical trials
from experience
9 11






Differences between inner-city and rural participants







Similarities between inner-city and rural participants
Not understanding clinical trials 17 15
Perceiving clinical trials as
being a guinea pig
4 6
Differences between inner-city and rural participants




Perceiving clinical trials as good care 7 12
Worrying about placebo 1 8
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clinical trial for somebody that, for example has sleep apnea.” These
advertisements may influence perceptions of clinical trials. Eliz-
abeth (rural) described one of these advertisements, stating that,
“laboratories want you to go in for, you know, a night or a week or
something like that on the TV on commercials, and they will, you
know, you're tested for different medicines and things.”
Participants said that most of these studies dealt with smoking
or being overweight, and emphasized the amount of dollars
received for participation. Some advertisements even position
participation in clinical trials as something to do “in between jobs”
or when searching for a job. For instance, Helen (inner-city) noted
that in one advertisement she viewed, you could “earn up to 1500
dollars to come to this place for three nights to participate in a
clinical trial.”
Inner-city and rural participants also heard about clinical trials
in the media through TV shows. Melissa (rural) mentioned hearing
about clinical trials in the TV show House. Helen (inner-city), who
identified herself as “a big Grey's Anatomy fan,” stated, “that's how I
knowmostly about clinical trials, is medical shows.” She added that
clinical trials are portrayed as a “last resort […] they've tried
everything else, and they're ondthey're basically on the dying list.
And they're reaching for anything because they're not ready to give
up.” Mark (rural) also heard about clinical trials in TV shows and
said that characters who participate in clinical trials “survive with
bad consequences.”
3.1.2. Learning about clinical trials from experience
The second most common way inner-city and rural participants
reported learning about clinical trials was via personal or vicarious
experience, such as “life experiences through different family
members,” as Jessica (inner-city) aid. Nancy (rural) stated, “my
husband has had cancer three times, the first time around with
lymphoma, and he had clinical trials then.” Even if they did not
know anybody who took part in a clinical trial, some participants
said that they had learned about clinical trials because of their
experience being a cancer patient for so long. For instance,Catherine (rural) stated, “I've been a patient for eight years. And so,
just throughout the years, you know, just through patient naviga-
tors, pamphlets, readings, and discussions with my doctor […] the
whole, I would say, oncology grapevine.” This “oncology grape-
vine,” as Catherine calls it, refers to discussions with various health
care providers, other patients and possible exposure to hospital
literature.
3.1.3. Relying on doctors-health care practitioners for information
Doctors represented the number one source inner-city and rural
participants reported relying on to get information about their
health/cancer. The following series of short quotes illustrate how
much participants rely on doctors: “I get my information from my
doctor” (Barbara, inner-city); “if I have a question, I usually ask the
doctor” (Richard, inner-city); “here at the hospital” (Nicole, inner-
city) “all that I know I have gotten from doctors” (Karen, rural);
“just relied on the doctor and the nurses” (Linda, rural); “my
physician, who I trust completely” (Amy, rural); “I normally ask my
doctor or the hospital or something like that” (Donald, rural).
Participants explained that they trust and value the opinion of
their doctors, who are usually also familiar with participants' rel-
atives. For instance, Barbara (inner-city) stated, “the doctor, mostly
because I go by what he tells me. He talks about different things
because he knows those in the family who have had breast cancer
since I had it.” However, and as discussed further below, while
participants in this study relied on their doctors for information
related to their disease, the majority of them also said that they had
never discussed clinical trials with their doctors.
3.1.4. Searching for health information online
Almost half of inner-city and rural participants mentioned using
the Internet to search for health information related to their cancer.
Richard (inner-city) stated, “I'll get on the Internet when I need
certain answers.” Carol (rural) was a little more detailed in her
answer, stating, “if I'm taking amedication and I'm having a little bit
of a side effect from that medication, I'll get on there [the Internet]
to see what the side effects of that medicine are.” Asked if she
obtained health information from other sources than her doctor
and the Internet, Lisa (rural) responded, “where else? That's about
all. The Internet is the only thing.” When asked if they visited
specific websites, about half of these participants responded
searching for information on WebMD, the Mayo Clinic, the Amer-
ican Cancer Society, the Susan G. Komen foundation, and the Na-
tional Cancer Institute. Some participants mentioned one or two
sources, while others said they started with a general Google
search.
3.2. Awareness of clinical trials: differences between inner-city and
rural participants
The main differences between inner-city and rural participants'
awareness of clinical trials were related to their visit to their
oncologist. Inner-city participants were more likely than rural
participants to learn about clinical trials from hospital literature
that they read while waiting to meet with their oncologist. Rural
participants were more likely than inner-city participants to report
that they did not discuss clinical trials with their oncologist.
3.2.1. Learning about clinical trials from hospital literature
About one third of inner-city participants learned about clinical
trials by reading hospital literature. For instance, James (inner-city)
stated, “when I walk into the doctor's office or in the hospital I see
things on the wall, I pick them up and read them, they have mag-
azines.”Michael (inner-city) stated, “whenever I go to the doctor on
my follow ups in those things I sit in, actually there are posters,
M. Geana et al. / Contemporary Clinical Trials Communications 5 (2017) 72e7976clinical trial posters saying how they help.” On the contrary, only
two rural participants reported reading hospital literature. Both
clinics where the study took place had generic posters about
participation in clinical trials displayed in the waiting rooms, but
none had any pamphlets or handouts about clinical trials available
to patients.
3.2.2. Not discussing clinical trials with doctors
Rural participants were much more likely to have reported not
discussing clinical trials with their doctors. Sandra (rural) stated, “I
just never ever; I have cancer and it's just a subject [clinical trials]
we [patient-provider] never discussed. I was never around that
type of thing, so I really never discussed this. I didn't even know it
was an option.” Most participants said that their oncologist only
discussed their treatment, as William (rural) stated, “my physician
just talked tome about howmy treatment was going and how I was
progressing until I was released from treatment.”
3.3. Perceptions of clinical trials: similarities between inner-city
and rural participants
Overall, inner-city and rural participants did not understand
what clinical trials are. While they reported different mis-
conceptions about clinical trials, as further discussed below, the
only similar misconception inner-city and rural participants held
about clinical trials was equating participation in a clinical trial to
being a guinea pig.
3.3.1. Not understanding clinical trials
When inner-city and rural participants were asked how they
would define or explain clinical trials, most of them could not
answer. Most participants' responses resembled that of Patricia
(inner-city), who said, “I don't know because I've never talked with
anyonewho has done that [a clinical trial],” or that of Robert (inner-
city), who said, “I don't really know exactly what it [clinical trial] is,
what it consists of.” Even participants who reported being familiar
with the term ‘clinical trial’ could not define or explain it. For
instance, Christopher (rural) stated, “I've heard of the name, but I
really and truly don't understand, you know, the scope or the depth
of what a clinical trial is.”
While most participants did not knowwhat a clinical trial was, a
few seemed particularly confused about it. George (inner-city) said
he was not sure if he had participated in a clinical trial or not,
stating, “I don't know if I'm still on the clinical trial, I know I've been
doing this for a while.” George was referring to his cancer treat-
ment, but did not know if his treatment was part of a clinical trial.
David (rural) thought that a phone interview could be a clinical
trial.
3.3.2. Perceiving clinical trials as being a guinea pig
A smaller, but similar number of inner-city and rural participants
perceived participating in a clinical trial as being a guinea pig in an
experiment. For instance, Kathleen (inner-city) emphasized this
point, stating, “it's experimental, you know, it's experimental, it's for
study, and of course that would put one in the position of a lab rat.”
Similarly, Stephanie (rural) stated, “I think, in my opinion, people
who are in a clinical trial aremoreof a guinea pig.”Consideringwhat
would make him participate in a clinical trial, Daniel (rural) stated,
“I'm not just going to be somebody's guinea pig.”
3.4. Perceptions of clinical trials: differences between inner-city and
rural participants
Inner-city and rural participants' differed in their perceptions of
clinical trials. Rural participants were more likely than inner-cityparticipants to perceive clinical trials as last resort treatments,
while inner-city participants were more likely than rural partici-
pants to understand the usefulness of clinical trials. In addition,
rural participants weremore likely to perceive clinical trials as good
care, yet they were also more likely to worry about receiving a
placebo.
3.4.1. Perceiving clinical trials as last resort
The most common misperception about clinical trials pertained
to being used only as a last resort. Rural participants were more
likely than inner-city ones to hold the view that clinical trials are
used when “there was absolutely no medicine that would help,” in
thewords of Dorothy (rural). Mark (rural) said that a “clinical trial is
probably the best last chance.” When asked to elaborate, he
answered, “well, when all the acceptedmethods have been tried, or
ruled out, and there's not much left for you to do other than try a
clinical trial.” These participants also mentioned the idea of clinical
trials as a last resort when responding to what would make them
consider taking part in a clinical trial. For instance, Melissa (rural)
stated, “if that's my only option, then, yeah, sure, I would be willing
to try something. If it wasn't, you know, if I had other options, then I
might not.”
3.4.2. Understanding the usefulness of clinical trials
Inner-city participants were more likely than rural ones to
perceive clinical trials as useful, as they commented on the signif-
icance of clinical trials. Patricia (inner-city) stated, “that medicine
I'm taking, that's coming from people on trial […] someone has
been in a trial process in order for these medicines todfor me to be
able to take them.” Elizabeth (inner-city) described clinical trials as
benefiting all parties involved, as they help “research people find
answers and it also helps the patient.” In the same way, Deborah
(inner-city) expressed her trust in and the value of clinical trials
stating, “I think that that's how we're going to cure cancer one day
is by a clinical trial.”
3.4.3. Perceiving clinical trials as good care
Rural participants were more likely than inner-city ones to
perceive clinical trials as good care. Karen (rural) stated, “I have had
no earlier experience but I'm aware that as the medical practice
goes, they're not going to do anything that's harmful to do.” Even if
something were to happen during the trials, these participants still
perceived clinical trials as safe, as Carol (rural) explained, “if the pill,
the medicine, don't agree with you they will take you off of it. So,
you're not in any harm's way and you are under a doctor's care and
they are very thorough making sure you are okay.”
3.4.4. Worrying about placebo
Despite perceiving clinical trials as good care, rural participants
were also more likely to report that they would worry about
receiving a placebo instead of an alternative treatment if they were
to participate in a cancer clinical trial. For instance, Edward (rural)
stated, “the way I understand it [clinical trial], not everybody gets
the real medicine. Some of them get placebos, and, you know, it
seems like people are not getting the benefit.” Similarly, Angela
(rural) stated, “I would not want to be in a group where I was given,
where I thought I was getting a drug for treatment and then given a
placebo.” Only one inner-city participant mentioned such
concerned.
4. Discussion
Findings reveal many similitudes between inner-city and rural
patients when it comes to sources of information and perception of
clinical trials. Both reported similar levels of awareness about
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websites, and personal experiences. The only differences dealt with
hospital literature and discussionwith doctors. In both cases, inner-
city participants reported more awareness about clinical trials from
brochures and oncologists. However, it is important to keep inmind
that regardless of these differences, overall, only a minority of
inner-city and rural participants reported reading hospital litera-
ture, and the majority of participants in both groups reported not
discussing clinical trials with their oncologists. This is particularly
problematic because both inner-city and rural participants also
reported relying on doctors and nurses for health-related
information.
In the present study, patients not being told about the thera-
peutic option to participate in a clinical trial highlights one of the
major problems facing accrual, in both inner-city and rural clinics.
The number of participants who stated not having discussed clin-
ical trials with their oncologist reflects what other researchers have
reported. Exploring cancer clinical trial awareness [43], found that
78% of the patients they surveyed had not received any information
about clinical trials from their general physicians, oncologists or
nurses. In their survey of oncologists [2], found that 55% of them
felt uncomfortable discussing the option of a clinical trial with their
patients. This significant absence of patient-provider discussions
about cancer clinical trials observed in the present study is highly
problematic for the clinics' effort to recruit clinical trial partici-
pants, given that other studies have repeatedly emphasized the
crucial role such discussions play in the enrollment of patients in
cancer clinical trials (e.g., [12,19,26,45,48].
Regarding awareness about clinical trials, most studies found
that the majority of patients are overall unaware of clinical trials
[13,29,33]. However, one study found that 84% of surveyed patients
were aware of clinical trials [51]. Our findings seem to support the
observation that patients may have heard about, but are less likely
to understand what clinical trials are. Three quarters of participants
in this study had heard about clinical trials from one or several
different sources. However, more than half of participants were
unable to explain what clinical trials entail or displayed mis-
perceptions about clinical trials. This may be related to having
mainly heard about clinical trial via media sources, such as televi-
sion shows and advertisements from large pharmaceutical com-
panies, neither of which emphasizes what clinical are, but are more
focused on the immediate financial benefits for the participants.
Indeed, these advertisements have been identified as some of the
many factors that contribute to low enrollments of patients in
cancer clinical trials conducted as part of federally funded research
studies. For instance [26], stated that, “of great concern are the large
number of industry-sponsored trials which frequently siphon pa-
tients from CTCG [Clinical Trials Cooperative Group] trials and
which usually offer much higher reimbursement rates.” (p. 1973).
Findings support the idea that media contribute to participants'
misunderstanding and misperceptions about clinical trials by only
associating themwith particular scenarios that usually do not apply
to patients' experiences.
Participants' comments reveal how little they know about
clinical trials, despite having been diagnosed with cancer, having
met with doctors and nurses, and visited hospitals multiple times.
In their survey of general public and cancer survivors [34], found
“low scores on the measure of clinical trial understanding” and
stressed that “public understanding of clinical trials needs to be
increased substantially” (p. 91). Even though most participants
could not explain how clinical trials work, some nevertheless held
specific views and opinions about clinical trials. Inner-city and rural
participants were as likely to perceive participating in a clinical trial
as being a guinea pig in an experiment, even though such per-
ceptions were only held by a minority of participants in bothgroups. Rural participants were more likely to perceive clinical
trials as good medical care, but also as being used as a last resort
and as potentially ineffective because of the chance of receiving a
placebo Inner-city participants weremore likely to perceive clinical
trials as useful to find new cures.
While some studies have reported that cancer patients' fear and/
or distrust of the medical system presents a barrier to clinical trial
enrollment [13,33], most participants in this study did not express
such concerns. On the contrary, the majority of participants clearly
stated that they trust their doctors and health-care practitioners
and mainly rely on them for information pertaining to their health.
Other studies have reported that associating taking part in a clinical
trial as being a guinea pig represents a major barrier to patient
enrollment in cancer clinical trials [13,26]. However, in the present
study, only a minority of participants expressed that idea. The most
common perception inner-city and rural participants held about
clinical trials dealt with receiving good medical care, thus rein-
forcing the trust participants have in the medical system.
4.1. Limitations
Results presented here need to take into account the study's
limitations. Participants were recruited from only two cancer
clinics in the Midwest. In addition, even though participants had
achieved different levels of education and came fromvarious socio-
economic backgrounds, most of them were White Americans. The
interviews addressed patient-provider discussions but these in-
teractions were not observed. Similarly, oncologists were not
interviewed to confirm what participants said. Future studies
should address these limitations and further explore the relation-
ship between media representations of clinical trials and patients'
perceptions of clinical trials, as media represented the main source
of participants' information about clinical trials.
5. Conclusion
The purpose of this study was to qualitatively explore inner-city
and rural cancer patients' awareness and perceptions of clinical
trials using patients' own words. As mentioned above, most pre-
vious studies either used quantitative methods such as surveys or
mainly included members of the non-diseased general population.
The present study thus contributes to communication efforts about
cancer clinical trials by focusing on understanding what patients
know and feel about clinical trials, and how they are similar or
differ based on attending an inner-city or rural cancer clinic.
Findings support previous studies' results regarding patients'
serious lack of awareness and understanding about (cancer) clinical
trials, and showcase the primordial importance of patient-provider
interaction to help recruit patients in clinical trials. Findings also
reveal that both inner-city and rural patients have limited aware-
ness, low understanding of the concept of clinical trials, and are
very passive in their engagement with information about cancer
clinical trials, as they expect and rely on doctors and nurses to
provide them with most of the health information they think they
need.
Findings also shed light on the prominent role mass media, and
especially commercials and television shows, play in forming pa-
tients' misperceptions about clinical trials. In addition, less than
half of the participants used the Internet to search for health in-
formation. Such findings suggest that despite the almost ubiquitous
use of online platforms in most communication efforts, changing
perceptions about clinical trials will most likely require an offline
two-prong approach, using doctors and nurses, as well as tradi-
tional media to communicate information and educate patients
about clinical trials.
M. Geana et al. / Contemporary Clinical Trials Communications 5 (2017) 72e7978These findings can help health communicators develop tailored
strategic communication messages to increase awareness, address
misperceptions, and accrue enrollment in cancer clinical trials. For
instance, videos featuring local nurses and doctors addressing pa-
tients' main misperceptions about clinical trials should be pro-
duced and played on monitors in clinics' waiting rooms. Cancer
patients should also receive a brochure about cancer clinical trials
that clearly explains how clinical trials are conducted, emphasize
the high quality of care clinical trial patients receive, and demystify
the notion that clinical trial patients are experimental guinea pigs.
Nurses and/or doctors should review the content of the brochure
with cancer patients and re-emphasize those points. Nurses and
doctors should also have a small booklet that includes key terms to
explain cancer clinical trials free of medical jargon and that lists the
main misperceptions they should address when discussing clinical
trials with patients. Significant attention should be given to address
health literacy concerns and making sure the information con-
tained in all printed and mediated materials is at an adequate
readability and comprehension level and is culturally tailored for
the patients.
Contrary to the barriers for patient participation in cancer
clinical trials identified in previous studies, findings from this study
suggest that the two main challenges to overcome for accrual to
cancer clinical trials are to increase awareness and change mis-
perceptions of clinical trials. These challengesmay bemore difficult
to overcome in rural areas than in inner-city ones, as rural patients
displayed less awareness and more misperceptions about clinical
trials compared to inner-city patients.
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